ORLANDO -- Tirzepatide (Zepbound) improved symptoms of moderate-to-severe obstructive sleep apnea (OSA) in people with obesity, regardless of positive airway pressure (PAP) use, the phase III SURMOUNT ...

Credit: Getty Images This patient fact sheet on sleep apnea and obesity discusses the bidirectional relationship between these 2 conditions and potential treatments. Our easy-to-read fact sheets ...

The Food and Drug Administration (FDA) has approved Zepbound ® (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity. Zepbound is a dual ...

As obesity medicine continues to evolve, integrating sleep health into obesity treatment plans is essential.Poor sleep ...

Obstructive sleep apnea was associated with increased risks for sarcopenia and sarcopenic obesity, especially among younger adults. Obstructive sleep apnea (OSA) is associated with an increased risk ...

Tirzepatide (Zepbound and Mounjaro), which is approved for chronic weight management and treatment of type 2 diabetes, has significant benefits for patients with moderate-to-severe obstructive sleep ...

Add Yahoo as a preferred source to see more of our stories on Google. The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe obstructive ...

Please provide your email address to receive an email when new articles are posted on . In patients with obesity and obstructive sleep apnea, weight-loss surgery was linked to reduced risk for heart ...

If you've been diagnosed with sleep apnea, you likely already know that a continuous positive airway pressure (CPAP) device ...

The FDA has expanded the approval of Eli Lillys obesity medication Zepbound to include treating moderate to severe obstructive sleep apnea for people with obesity -- the first medication approved for ...